The test group was treated with voriconazole injection in combination with three or more antibacterial drugs, and the control group was treated with voriconazole injection in combination with 1-2 antibacterial drugs. The sample was matched by propensity score matching method, and the prognosis of the test group and the control group was compared by antifungal effectiveness and incidence of adverse drug reactions.
Introduction
With its high morbidity and mortality, Invasive fungal infection (IFI) has long been a major threat for patients with malignant blood disease (MBD), IFIs mainly occur in patients with acute myeloid leukemia, and the incidence rate is about 34.6-48.4% [1, 2] .
Voriconazole is a new generation of triazole antifungal drugs. With merits of a broad antibacterial spectrum, prominent antifungal effect, and high bioavailability. It has a good preventive and therapeutic effects in Candida and Aspergillus fungal infections, and have become the first line of invasive Aspergillus infection [3] . In clinical use, voriconazole injection is often combined with antibacterial drugs. This study aimed to investigate the effect of voriconazole injection combined with three or more antibacterial agents on prophylaxis and treatment of hematological malignancies with invasive fungal infections.
Objectives and Methods

General Information
Retrospective collection and analysis of patients who were admitted to our department of Hematology and applied voriconazole injection combined with antibacterial drugs from May 1, 2018 to April 30, 2019. The test group was voriconazole injection combined with 3 or more antibacterial drugs, the control group was voriconazole injection combined with 1-2 antibacterial drugs. 
Inclusion or Exclusion
Outcome Indicators
Outcomes measured Included the effectiveness rate and the incidence of adverse events in two groups patients. Effective 
Statistical Methods
Data from the control and intervention groups was matched by the means of propensity score matching (PSM), with the caliper of neutrophil deficiency time≥7 days in the experimental group were significantly higher for the test group compared to the control group, significant number (P<0.05); see Table 1 for details. 60 cases were left in each group after PSM. The age, sex, hospitalization time, disease type, chemotherapy, neutrophil deficiency time ≥7 days, past medical history, medication purpose have no significant difference (P>0.05). The baseline data of the two groups were balanced before being compared. matched samples were used for comparative analysis. See Table 1 for details. 
Discussion
The widespread use of antibacterial drugs in clinical practice has led to the development of drug-resistant strains in patients, and the widespread use of broad-spectrum antibiotics can not only kill sensitive pathogens, but also kill normal strains and easily cause fungal infections [6] . However, long-term use of broad-spectrum antibiotics can lead to neutropenia, and reduce V's microbicidal ability in inhibiting growth mycelial cell walls in fungi, and not effectively destroy the fungal mycelial cell wall [7] . We are still working to include more individual level data for scaling up our researches to draw clearer and more generalized conclusions.
However, our observation that the effectiveness of voriconazole is reduced after the combination of more than three antibacterial drugs, and we are doing further large-scale research, and our later conclusions will continue to be published in the form of papers. The views of this study would provide with clues in promoting clinical rational drug use from the perspective of both safety and efficacy.
